Chinese clinical-stage, oncology-focused biotech player IASO Biotherapeutics on Monday announced the completion of its $60-million Series B round of financing led by Hillhouse’s early-stage venture capital fund GL Ventures.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
